MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.25 (26.91% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Piper JaffrayReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.31)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)
Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline
06/25/16 09:11 AMNektar Therapeutics (NASDAQ:NKTR) Yearly Sales Target At $448.69 - Investor Newswire
06/23/16 08:10 AMDover Corporation (NYSE:DOV) Median EPS Target At $1.025
06/23/16 08:10 AMBIND Therapeutics : Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
06/22/16 05:21 PMStrong Buy Calls Count For Nektar Therapeutics (NASDAQ:NKTR) At 7 - Investor Newswire
06/22/16 05:21 PMNektar Therapeutics (NASDAQ:NKTR) Analyst Rating Consensus - TheFounders Daily
06/20/16 05:20 PMNektar Therapeutics (NKTR) take heat post earnings
06/20/16 02:42 PMNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : June 20, 2016 -
06/14/16 07:40 AMNektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : June 14, 2016 -
06/11/16 05:38 PMAnalyst Suggestions Roundup: Brunswick Corporation (NYSE:BC), Nektar Therapeutics (NASDAQ:NKTR) - Beacon Chronicle
06/11/16 08:18 AMNektar Therapeutics (NASDAQ:NKTR) Yearly Sales Estimate At $448.689 - Investor Newswire
06/10/16 08:23 AMStocks within investor Spotlight: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates
06/09/16 05:48 PMEarnings Overview: Nektar Therapeutics (NASDAQ:NKTR), Thermo Fisher Scientific, Inc. (NYSE:TMO) - Beacon Chronicle
06/09/16 08:24 AMNektar Therapeutics (NASDAQ:NKTR) Fundamental Star Rating Report - CML News
06/06/16 01:18 PMPreclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity - [at noodls] - SAN FRANCISCO, June 6, 2016 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated ...
06/06/16 01:01 PM2:01 pm Nektar Therapeutics data presented at ASCO demonstrated that single-agent NKTR-214 produces a large increase in tumor-infiltrating lymphocytes to provide durable anti-tumor activity -
06/06/16 09:07 AMTraded Price Fluctuations to Observe: CTI BioPharma Corp. (NASDAQ:CTIC) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates
06/06/16 09:07 AMInsider Trading Alert: Nektar Therapeutics (NASDAQ:NKTR) - The Point Review
06/05/16 05:27 PMPerformance Review for Nektar Therapeutics (NASDAQ:NKTR) - HNN
06/05/16 08:08 AMNektar Therapeutics (NKTR) Earns Buy Rating from Piper Jaffray - Let Me Know About This
06/04/16 05:30 PMTop 2 Stocks To Buy: Nektar Therapeutics (NASDAQ:NKTR), SBA Communications Corp. (NASDAQ:SBAC) - Beacon Chronicle
06/03/16 08:18 AMWorth Watching Stocks: Kite Pharma Inc(NASDAQ:KITE), Nektar Therapeutics(NASDAQ:NKTR) - NYSE Journal (press release) - Worth Watching Stocks: Kite Pharma Inc(NASDAQ:KITE), Nektar Therapeutics(NASDAQ:NKTR)NYSE Journal (press release)On Thursday, Shares of Kite Pharma Inc (NASDAQ:KITE), added 7.86% and closed at $54.87 in the last trading session. The last trading range of the stock ranges between $50.73 and $54.95. Kite Pharma, Inc. (KITE) (“Kite”) and Cell Design Labs, Inc.and more »
06/02/16 05:50 PMAnalysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and The Spectranetics ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR) and The Spectranetics ...Analyst RatingsAschoff noted, “Nektar announced this morning that it has entered into a collaboration agreement with Daiichi Sankyo Europe for ONZEALD (NKTR-102), which has completed the Phase 3 BEACON trial in patients with advanced breast cancer. Nektar granted ...
06/02/16 05:50 PMStock's Price Moves: Nektar Therapeutics (NASDAQ:NKTR) , Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Street Updates - Stock's Price Moves: Nektar Therapeutics (NASDAQ:NKTR) , Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Street UpdatesOn 6/1/2016, Nektar Therapeutics (NASDAQ:NKTR) highlighted upward shift of +0.58% or +0.09 points to $15.53. The company traded a volume of 1.19 million shares over average volume of 1.14 million shares. Trailing twelve month period, the firm has ...and more »
06/02/16 05:45 PMNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City - [at noodls] - SAN FRANCISCO, June 2, 2016 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare ...
06/02/16 03:57 PMBRIEF-Nektar therapeutics says Gil Labrucherie named CFO - * Nektar Therapeutics says Gil M. Labrucherie has been named senior vice president & chief financial officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223...
06/02/16 08:24 AMEarnings Report of the Stock: Nektar Therapeutics (NASDAQ:NKTR), Bruker Corporation (NASDAQ:BRKR) - Beacon Chronicle - Earnings Report of the Stock: Nektar Therapeutics (NASDAQ:NKTR), Bruker Corporation (NASDAQ:BRKR)Beacon ChronicleLast Trade: The Company closed its last session at $15.53 with the gain of 0.58%. The market capitalization of the company is $2.11 Billion, with the average Volume of 1.14 Million. The stock currently has its 52-Week High range of $17.55 and 52-week ...and more »
06/02/16 07:37 AMNektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald -
06/01/16 08:22 AMNektar Therapeutics (NKTR), Daiichi Sankyo Europe Ink ONZEALD Licensing Agreement - StreetInsider.com - Nektar Therapeutics (NKTR), Daiichi Sankyo Europe Ink ONZEALD Licensing AgreementStreetInsider.comNektar Therapeutics (Nasdaq: NKTR) announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the ...Floating Price Update: Nektar Therapeutics (NASDAQ:NKTR) , Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Street UpdatesTwo Biotech Stocks Are Just So Hot Right Now: Nektar Therapeutics (NKTR), Galena Biopharma (GALE)ZergwatchUpgrades And Downgrades For Nektar Therapeutics (NASDAQ:NKTR)Risers & FallersHNNall 5 news articles »
06/01/16 07:23 AMNEKTAR THERAPEUTICS Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure -
06/01/16 07:23 AMNektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases - [at noodls] - SAN FRANCISCO, June 1, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ...
05/31/16 09:27 AMNektar Therapeutics (NASDAQ:NKTR) Quarterly EPS Estimate At $-0.30 - Investor Newswire - Nektar Therapeutics (NASDAQ:NKTR) Quarterly EPS Estimate At $-0.30Investor NewswireFirst Call stated that Nektar Therapeutics (NASDAQ:NKTR) can touch $17.43 in coming one year. For the next quarter, the per-share earnings target is $-0.30 and for ongoing fiscal at $-0.97. EPS target for next year is $-0.71 versus the mean EPS of $-1 ...and more »
05/30/16 10:04 PMTarget Check and Stock Performance Recap Nektar Therapeutics (NASDAQ:NKTR) - HNN - Target Check and Stock Performance Recap Nektar Therapeutics (NASDAQ:NKTR)HNNIn recent session activity, Nektar Therapeutics (NASDAQ:NKTR) shares have traded +1.81%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been recorded ...and more »
05/30/16 10:04 PMStock Review and Earnings Check on Nektar Therapeutics (NASDAQ:NKTR) - HNN - Stock Review and Earnings Check on Nektar Therapeutics (NASDAQ:NKTR)HNNCurrently, sell-side analysts are expecting Nektar Therapeutics (NASDAQ:NKTR) to report quarterly EPS of $-0.3. The company's next earnings report is expected to be published on or around 2016-08-03 for the period ending on 2016-06-30. The company ...and more »
05/26/16 05:58 AMInvestors Attention Alert: Nektar Therapeutics (NASDAQ:NKTR) , STERIS Corporation (NYSE:STE) - Street Updates - Investors Attention Alert: Nektar Therapeutics (NASDAQ:NKTR) , STERIS Corporation (NYSE:STE)Street UpdatesNektar Therapeutics (NASDAQ:NKTR) accumulated +3.34%, closing at $14.54 after floating between $13.89 and $14.59. The company has market capitalization of $1.98B. It has twelve month low of $9.16 and twelve month high of $17.55. The recent traded ...and more »
05/25/16 07:47 AMNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 25, 2016 -
05/24/16 11:05 AMEarnings Review and Stock Rundown for Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Nektar Therapeutics (NASDAQ:NKTR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Nektar Therapeutics (NASDAQ:NKTR) to post ...and more »
05/23/16 09:24 PMTop Stories: SAExploration Holdings, Inc. (NASDAQ:SAEX), Nektar Therapeutics (NASDAQ:NKTR), Nanometrics ... - KC Register - Top Stories: SAExploration Holdings, Inc. (NASDAQ:SAEX), Nektar Therapeutics (NASDAQ:NKTR), Nanometrics ...KC RegisterBrean Capital restated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a report published. A number of other analysts have also commented on NKTR. Zacks Investment Research raised shares of Nektar Therapeutics from a strong sell ...
05/23/16 09:24 PMTarget Check and Stock Performance Recap Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Hints and News - Target Check and Stock Performance Recap Nektar Therapeutics (NASDAQ:NKTR)Wall Street Hints and NewsIn recent session activity, Nektar Therapeutics (NASDAQ:NKTR) shares have traded +3.36%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been recorded ...and more »
05/23/16 09:24 PMStock's Price Swings: Quest Diagnostics Incorporated (NYSE:DGX) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates - Stock's Price Swings: Quest Diagnostics Incorporated (NYSE:DGX) , Nektar Therapeutics (NASDAQ:NKTR)Street UpdatesIn the past trading session, Nektar Therapeutics (NASDAQ:NKTR) highlighted upward shift of +3.36% or +0.45 points to $13.84. The company traded a volume of 844.17 thousand shares under average volume of 1.18 million shares. Trailing twelve month ...and more »
05/23/16 12:06 AMPerformance at a Glance on Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Hints and News - Performance at a Glance on Nektar Therapeutics (NASDAQ:NKTR)Wall Street Hints and NewsWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Nektar Therapeutics (NASDAQ:NKTR)'s stock has performed at various points in its past. Currently, the ...and more »
05/21/16 07:01 PMNektar Therapeutics (NASDAQ:NKTR) One-Year Price Target Estimate At $17.43 - Investor Newswire - Nektar Therapeutics (NASDAQ:NKTR) One-Year Price Target Estimate At $17.43Investor NewswireThe 52-week price target of Nektar Therapeutics (NASDAQ:NKTR) is set at $17.43 after First Call completed its market based survey. It has estimated EPS of $-0.30 for approaching quarter and $-0.97 for ongoing year. The EPS estimate for next year is $-0 ...and more »
05/20/16 10:57 AMETF’s with exposure to Nektar Therapeutics : May 20, 2016 -
05/19/16 10:29 AMRobin Howard W, President & CEO of Nektar Therapeutics (NASDAQ:NKTR) sells 2,170 shares - According to Nektar Therapeutics's most recent Form 4 filing with the SEC dated May 18 05:23 PM, company President & CEO, Robin Howard W disclosed selling 2,170 shares at a cost of $13.58. At the time of this transaction (May 17), this trade was worth $ ...
05/17/16 07:15 PMShare Recap and Earnings Focus on Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Hints and News - Share Recap and Earnings Focus on Nektar Therapeutics (NASDAQ:NKTR)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Nektar Therapeutics ...and more »
05/17/16 02:22 PMNektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 01:05 PMPrice Fluctuations to Observe: Trevena, Inc. (NASDAQ:TRVN) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates - Price Fluctuations to Observe: Trevena, Inc. (NASDAQ:TRVN) , Nektar Therapeutics (NASDAQ:NKTR)Street UpdatesNektar Therapeutics (NASDAQ:NKTR) moved in green zone with rise of +0.23 points or +1.76% to $13.32. The company has a market worth of $1.82B.Total 541.54 thousand shares were exchanged in last trading session as opposed to average volume of ...Nektar Therapeutics Could Burn Your Portfolio. The Stock Formed Bearish Head & Shoulders PatternThe Postall 2 news articles »
05/13/16 12:20 AMEarnings per share overview: Nektar Therapeutics (NASDAQ:NKTR) - News Oracle - Earnings per share overview: Nektar Therapeutics (NASDAQ:NKTR)News OracleLast Trade: The Company fell -3.06% and finished at $13.29. The daily volume was measured at 560,931.00 shares. The 52-week high of the share price is $17.55 and the 52-week low is $9.16. The company has a market cap of $1.83 Billion. Its latest ...Stocks within investor Spotlight: Laboratory Corporation of America Holdings (NYSE:LH) , Nektar Therapeutics ...Street Updatesall 4 news articles »
05/09/16 12:36 AMNektar Therapeutics (NASDAQ:NKTR) Broker Price Targets For The Coming Week - Share Trading News - Nektar Therapeutics (NASDAQ:NKTR) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Nektar Therapeutics (NASDAQ:NKTR). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/07/16 07:06 PMNektar Therapeutics (NASDAQ:NKTR) Yearly EPS Target At $-0.97 - Investor Newswire - Nektar Therapeutics (NASDAQ:NKTR) Yearly EPS Target At $-0.97Investor NewswireAs per Thomson Reuters, b>Nektar Therapeutics (NASDAQ:NKTR) can touch $17.43 in coming 52-weeks. The mean EPS, a year earlier was $-0.56. For the coming quarter, the EPS estimate is $-0.30 while for this fiscal the set target is $-0.97. The per share ...and more »
05/04/16 03:52 PMWhy Nektar Therapeutics Inc Is Dropping Today -
About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Company's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $14.38
  • 50 Day Moving Average: $14.72
  • 200 Day Moving Average: $14.18
  • P/E Ratio: N/A
  • P/E Growth: 2.22
  • Market Cap: $1.96B
  • Current Quarter EPS Consensus Estimate: $-0.96 EPS
Additional Links:
Nektar Therapeutics (NASDAQ:NKTR) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha